Adverse Events Following Pneumococcal Vaccination among Infants attending Immunization Clinic at a Tertiary Hospital in Northern India
Keywords:Side effects, AEFI, PCV-13, Haryana
Background: Pneumococcal conjugate vaccine (PCV-13) has been introduced in India in a phased manner. In Haryana it was introduced in 2017. The adverse events following immunization (AEFI) with PCV in real community setting are yet to be detected. Objective: To calculate the incidence and associated factors for various AEFI after pneumococcal vaccination at a tertiary centre of Faridabad, Haryana. Methodology: The descriptive observational study was conducted from April through October 2019 at the immunization centre of a tertiary care centre of Faridabad, Haryana. Each dose of PCV-13 given to the infants attending immunization centre was the study unit. A telephonic contact was done within 24 hours, after 48 hours and between 5-7 days to enquire about any adverse events (minor & major), if occurred. Results: A total of 135 PCV-13 doses were followed up for any AEFIs. 113 AEFIs (incidence: 67.3 per 100 dose) reported in 93 infants. Incidence of fever was 45 per 100 dose followed by tenderness and erythema (39 per 100 doses for each). Incidence of Swelling was 21 per 100 doses. Conclusion: Active surveillance and co administration of Pentavalent vaccine could have resulted in higher proportion of AEFIs.
Rodgers GL, Klugman KP. The future of pneumococcal disease prevention.Vaccine. 2011 Sep 14;29 Suppl 3:C43-8. doi: 10.1016/j.vaccine.2011.07.047. PMID:21896352.[PubMed]
Varghese R, Veeraraghavan B, Jeyaraman Y, Kumar G, Arora NK, BalasubramanianS. Pneumococcal conjugate vaccine rollout in India: Expectations and challenges.Indian J Med Microbiol. 2019 Apr-Jun;37(2):141-146. doi:10.4103/ijmm.IJMM_19_320. PMID: 31745013.[PubMed].
Littlejohn ES,Clothier HJ, Perrett KP, Danchin M. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia. Human Vaccines &Immunotherapeutics. 2015; 11(7): 1828-35.
Ratnam S, West R, Gadag V. Measles and rubella antibody response aftermeasles-mumps-rubella vaccination in children with afebrile upper respiratorytract infection. J Pediatr. 1995 Sep;127(3):432-4. doi:10.1016/s0022-3476(95)70077-3. PMID: 7658276.[PubMed].
Cilla G, Peña B, Marimón JM, Pérez-Trallero E. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.Vaccine. 1996 Apr;14(6):492-4. doi: 10.1016/0264-410x(95)00234-r. PMID: 8782345.[PubMed].
WHO. Introduction of pneumococcal vaccine PCV13, A handbook for district and health facility staff. October 2013. Available from www.who.int/vaccines-documents.[Last accessed on 10th April, 2020]
Ahmad S, Pal J, Das A, Samanta S. Adverse events following immunization with pentavalent vaccine among infants attending the immunization clinic at a tertiary hospital in Eastern India. Int J Community Med Public Health 2017;4:2570-5.
Sebastian J, Gurumurthy P, Ravi MD, Ramesh M. Active surveillance of adverseevents following immunization (AEFI): a prospective 3-year vaccine safety study.Ther Adv Vaccines Immunother. 2019 Nov 21;7:2515135519889000. doi:10.1177/2515135519889000. PMID: 31799496; PMCID: PMC6873273.[PubMed]
Evans G. Vaccine injury compensation programs worldwide. Vaccine. 1999;17(supplement 3):S25–S35
How to Cite
Copyright (c) 2020 Indian Journal of Community Health
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.